Cargando…
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
BACKGROUND: Mutations in isocitrate dehydrogenase (IDH)1 or -2 are found in ~50% of conventional central chondrosarcomas and in up to 87% of their assumed benign precursors enchondromas. The mutant enzyme acquires the activity to convert α-ketoglutarate into the oncometabolite d-2-hydroxyglutarate (...
Autores principales: | Cleven, Arjen H. G., Suijker, Johnny, Agrogiannis, Georgios, Briaire-de Bruijn, Inge H., Frizzell, Norma, Hoekstra, Attje S., Wijers-Koster, Pauline M., Cleton-Jansen, Anne-Marie, Bovée, Judith V. M. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418698/ https://www.ncbi.nlm.nih.gov/pubmed/28484589 http://dx.doi.org/10.1186/s13569-017-0074-6 |
Ejemplares similares
-
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
por: Suijker, Johnny, et al.
Publicado: (2015) -
No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
por: Peterse, Elisabeth F. P., et al.
Publicado: (2016) -
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
por: Venneker, Sanne, et al.
Publicado: (2020) -
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019) -
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)